Data I/O closes $9 million private placement with two investors

Data I/O Corporation (NASDAQ: DAIO) has closed a previously announced securities purchase agreement with two institutional investors, raising $9 million in aggregate gross proceeds before placement agent fees and offering expenses.

Under the terms of the agreement, the Redmond, Wash.-based company issued 869,840 shares of common stock, convertible debentures with an aggregate principal amount of approximately $6.8 million, and warrants to purchase up to 1,080,000 shares of common stock.

The warrants carry an exercise price of $3.00 per share and are exercisable for five years from the date of issuance. The unsecured convertible debentures bear interest at 4.0% per annum, payable in cash or Series B preferred stock at the company's discretion, and mature on the fifth anniversary of issuance. The debentures are convertible into Series B preferred stock, which carries an initial conversion price of $2.50 per share into common stock. The Series B preferred stock is non-voting.

The convertible debentures will automatically convert into Series B preferred stock upon stockholder approval at an upcoming shareholders meeting, as required under Nasdaq rules.

Data I/O stated it intends to use the net proceeds for working capital, general corporate purposes, and potential strategic acquisitions. Ladenburg Thalmann & Co. acted as exclusive placement agent, and Benchmark, a StoneX company, served as financial advisor.

The securities were sold in a private placement and have not been registered under the Securities Act of 1933. Data I/O said it has agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the shares issued, as well as shares issuable upon warrant exercise and preferred stock conversion.

You May Also Be Interested In

• Genuine Parts names leaders for planned split into two companies
• Brightline Interactive signs MOU with George Mason University
• Tyra Biosciences reports Phase 2 data for oral bladder cancer drug